AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32965602 — intervention group
Group type: COMPARATOR
Intervention: Rituximab reference product
Number of subjects: 0
Study 35232894 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-9701 (30 mg, 3 times a day for 4 weeks)
Number of subjects: 60
Study 35232894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32321478 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong-fear-plus-empowerment message
Number of subjects: 4000
Study 32321478 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-fear-plus-empowerment message
Number of subjects: 4000
Study 32321478 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-alone message
Number of subjects: 4000
Study 32321478 — intervention group
Group type: EXPERIMENTAL
Intervention: All messages (not 'very/somewhat new')
Number of subjects: 4000
Study 35101346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus avelumab (rechallenge therapy)
Number of subjects: 77
Study 33650779 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg/day)
Number of subjects: 40
Study 33650779 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (0.3–0.9 mg/day)
Number of subjects: 40
Study 35658800 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW (1 hour/week)
Number of subjects: 52
Study 35658800 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD (2 hours/week)
Number of subjects: 52
Study 35658800 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 52
Study 34419277 — intervention group
Group type: COMPARATOR
Intervention: Control group (milk replacer only)
Number of subjects: 83
Study 34419277 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk replacer mixed with antirotavirus antibodies
Number of subjects: 83
Study 34419277 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum replacer mixed with antirotavirus antibodies
Number of subjects: 83
Study 33714487 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release maneuver (MLM) applied to lower limb muscle chains
Number of subjects: 63
Study 33714487 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 63
Study 36001544 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual clinical examination using ICDAS
Number of subjects: 80
Study 36001544 — intervention group
Group type: EXPERIMENTAL
Intervention: iTero Element 5D System (intraoral scanner with near infrared imaging technology)
Number of subjects: 80
Study 36001544 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitewing radiography (BWX)
Number of subjects: 80
Study 34189603 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated diet cola (CAF)
Number of subjects: 13
Study 34189603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cola containing caffeine and carbohydrates (CAF+CHO)
Number of subjects: 13
Study 34189603 — intervention group
Group type: COMPARATOR
Intervention: Flattened decaffeinated diet cola (PLA)
Number of subjects: 13
Study 35387611 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Vector Management (IVM) combining targeted outdoor residual spraying (TORS), deployment of auto-dissemination devices (ADDs), and active community engagement (CE)
Number of subjects: 0
Study 35387611 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted outdoor residual spraying (TORS)
Number of subjects: 0
Study 35387611 — intervention group
Group type: EXPERIMENTAL
Intervention: Deployment of auto-dissemination devices (ADDs)
Number of subjects: 0
Study 35387611 — intervention group
Group type: EXPERIMENTAL
Intervention: Active community engagement (CE)
Number of subjects: 0
Study 34346165 — intervention group
Group type: COMPARATOR
Intervention: Single intravenous dose of NL005 (0.05, 0.25, 0.5, 2.0, 5.0, 12.5 or 25.0 μg/kg)
Number of subjects: 54
Study 34346165 — intervention group
Group type: COMPARATOR
Intervention: Multiple intravenous doses of NL005 (0.5, 2.0 and 5.0 μg/kg) administered once daily for 10 days
Number of subjects: 54
Study 32989366 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician recommendation for HPV vaccination
Number of subjects: 317
Study 32989366 — intervention group
Group type: EXPERIMENTAL
Intervention: Various factors associated with HPV vaccine hesitancy
Number of subjects: 317
Study 32586143 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment HDL in the lowest quartile (≤ 1.21 mmol/l)
Number of subjects: 8267
Study 32586143 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment HDL in the second and third quartiles
Number of subjects: 8267
Study 32586143 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HDL in the lowest quartile (≤ 1.21 mmol/l)
Number of subjects: 8267
Study 32586143 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment HDL in the lowest quartile
Number of subjects: 8267
Study 32586143 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HDL ≤ 1.21 mmol/l
Number of subjects: 8267
Study 36040917 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/ezetimibe with clopidogrel or ticagrelor
Number of subjects: 0
Study 36040917 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/ezetimibe with ticagrelor
Number of subjects: 0
Study 36040917 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin with ticagrelor
Number of subjects: 0
Study 33420951 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (Arm A)
Number of subjects: 160
Study 33420951 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (Arm B)
Number of subjects: 160
Study 33420951 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib-Pravastatin combination (Arm C)
Number of subjects: 160
Study 33420951 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (Arm D)
Number of subjects: 160
Study 33420951 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (not treated with sorafenib)
Number of subjects: 160
Study 33420951 — intervention group
Group type: COMPARATOR
Intervention: Not treated with sorafenib
Number of subjects: 160
Study 33420951 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (in ALBI grade 1/2)
Number of subjects: 160
Study 33420951 — intervention group
Group type: COMPARATOR
Intervention: Not treated with sorafenib (in ALBI grade 1/2)
Number of subjects: 160
Study 34847564 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (group-exercise training once weekly and independent exercises at home twice weekly for 24 weeks)
Number of subjects: 60
Study 34847564 — intervention group
Group type: COMPARATOR
Intervention: Control group (general care)
Number of subjects: 60
Study 35355441 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF patients
Number of subjects: 645
Study 35355441 — intervention group
Group type: COMPARATOR
Intervention: HFrEF patients
Number of subjects: 645
Study 33631112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ublituximab plus ibrutinib
Number of subjects: 126
Study 33631112 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib alone
Number of subjects: 126
Study 36162037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg/kg once every 6 weeks
Number of subjects: 1833
Study 36162037 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab 480 mg once every 4 weeks
Number of subjects: 1833
Study 34441023 — intervention group
Group type: EXPERIMENTAL
Intervention: New classification of diabetic foot syndrome adapted for ICD-10
Number of subjects: 492
Study 32461038 — intervention group
Group type: COMPARATOR
Intervention: No psychotropic drugs
Number of subjects: 431
Study 32461038 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥3 psychotropic drugs
Number of subjects: 431
Study 32461038 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of antidepressant agents in mild and moderate dementia
Number of subjects: 431
Study 91215444 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing
Number of subjects: 1004
Study 91215444 — intervention group
Group type: COMPARATOR
Intervention: Stapling
Number of subjects: 1004
Study 35995102 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual-brand cigarettes
Number of subjects: 775
Study 35995102 — intervention group
Group type: EXPERIMENTAL
Intervention: Study cigarettes (0.4, 2.4, 15.8 mg/g)
Number of subjects: 775
Study 35995102 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg/g nicotine content
Number of subjects: 775
Study 34283906 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly educational SMS for 6 months
Number of subjects: 128
Study 34283906 — intervention group
Group type: COMPARATOR
Intervention: No SMS at all (control group)
Number of subjects: 128
Study 35809280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided thoracic paravertebral block before induction of ropivacaine+butorphanol anesthesia
Number of subjects: 100
Study 35809280 — intervention group
Group type: COMPARATOR
Intervention: Routine operation anesthesia
Number of subjects: 100
Study 32466811 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment plus treatment as usual (MBTp + TAU)
Number of subjects: 84
Study 32466811 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 84
Study 32284053 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 mg sucralose
Number of subjects: 137
Study 32284053 — intervention group
Group type: EXPERIMENTAL
Intervention: 96 mg sucralose
Number of subjects: 137
Study 32284053 — intervention group
Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 137
Study 34498314 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus thiopurines (combination therapy)
Number of subjects: 620
Study 34498314 — intervention group
Group type: COMPARATOR
Intervention: Infliximab monotherapy
Number of subjects: 620
Study 34498314 — intervention group
Group type: COMPARATOR
Intervention: Overall cohort (combination therapy vs. monotherapy)
Number of subjects: 620
Study 34498314 — intervention group
Group type: COMPARATOR
Intervention: MarketScan cohort
Number of subjects: 620
Study 34498314 — intervention group
Group type: COMPARATOR
Intervention: Optum cohort
Number of subjects: 620
Study 34498314 — intervention group
Group type: COMPARATOR
Intervention: SNDS cohort
Number of subjects: 620
Study 32312265 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 100
Study 32312265 — intervention group
Group type: COMPARATOR
Intervention: Exercise + placebo
Number of subjects: 100
Study 32312265 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + ICT
Number of subjects: 100
Study 32312265 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + SDT
Number of subjects: 100
Study 32312265 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + PHOTO
Number of subjects: 100
Study 35945719 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy along with tennis ball myofascial release (6 sessions, 35 minutes/session for 4 weeks)
Number of subjects: 22
Study 35945719 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy only (control group, n=11)
Number of subjects: 22
Study 35945719 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy along with tennis ball myofascial release
Number of subjects: 22
Study 35945719 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy only (control group)
Number of subjects: 22
Study 34397084 — intervention group
Group type: EXPERIMENTAL
Intervention: Spin identified in RCT abstracts
Number of subjects: 111
Study 34397084 — intervention group
Group type: EXPERIMENTAL
Intervention: Spin in Results section
Number of subjects: 111
Study 34397084 — intervention group
Group type: EXPERIMENTAL
Intervention: Spin in Conclusions section
Number of subjects: 111
Study 34397084 — intervention group
Group type: COMPARATOR
Intervention: International collaboration
Number of subjects: 111
Study 34397084 — intervention group
Group type: COMPARATOR
Intervention: Trial registration
Number of subjects: 111
Study 32957318 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hypertonic saline (HTS), 0.63 ml/kg, administered as a bolus via a central venous catheter, infused over 15 minutes
Number of subjects: 83
Study 32957318 — intervention group
Group type: COMPARATOR
Intervention: 20% mannitol, 2 ml/kg, administered as a bolus via a central venous catheter, infused over 15 minutes
Number of subjects: 83
Study 35790456 — intervention group
Group type: EXPERIMENTAL
Intervention: Disaster nursing and management education program (8 modules, theoretical and applied components)
Number of subjects: 131
Study 33340721 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week specialized handgrip strength training program (TG)
Number of subjects: 36
Study 33340721 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36
Study 32508363 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapy with quetiapine or lamotrigine
Number of subjects: 0
Study 32508363 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (lithium or divalproex)
Number of subjects: 0
Study 36111589 — intervention group
Group type: EXPERIMENTAL
Intervention: Exufiber®
Number of subjects: 248
Study 36111589 — intervention group
Group type: COMPARATOR
Intervention: Aquacel® Extra™
Number of subjects: 248
Study 34181506 — intervention group
Group type: COMPARATOR
Intervention: Two doses of measles‐mumps‐rubella (MMR) vaccine
Number of subjects: 827
Study 34181506 — intervention group
Group type: EXPERIMENTAL
Intervention: Not vaccinated against varicella
Number of subjects: 827
Study 34181506 — intervention group
Group type: COMPARATOR
Intervention: MMR vaccine
Number of subjects: 827
Study 32676780 — intervention group
Group type: COMPARATOR
Intervention: 1 g TXA via intravenous injection and 1 g TXA for external use (Group B)
Number of subjects: 599
Study 32676780 — intervention group
Group type: COMPARATOR
Intervention: 10 mg rivaroxaban qd for 35 days after surgery (Group C)
Number of subjects: 599
Study 32676780 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of TXA and rivaroxaban (Group D)
Number of subjects: 599
Study 34365063 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg IM ketorolac
Number of subjects: 110
Study 34365063 — intervention group
Group type: COMPARATOR
Intervention: 60 mg IM ketorolac
Number of subjects: 110
Study 32380977 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrographolide (AP) 140 mg orally twice daily for 24 months
Number of subjects: 44
Study 32380977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 32380977 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrographolide (AP)
Number of subjects: 44
Study 35537503 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Occlusion (LAAO) with post-procedural dual antiplatelet therapy (DAPT)
Number of subjects: 609
Study 35537503 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antithrombotic therapy or DAPT as deemed appropriate)
Number of subjects: 609
Study 32572472 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 vaccine
Number of subjects: 22
Study 35325846 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% lidocaine with paracetamol
Number of subjects: 184
Study 35325846 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% lidocaine with ibuprofen
Number of subjects: 184
Study 35325846 — intervention group
Group type: COMPARATOR
Intervention: Oral paracetamol alone
Number of subjects: 184
Study 35325846 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen alone
Number of subjects: 184
Study 33827502 — intervention group
Group type: EXPERIMENTAL
Intervention: Village Health Teams (VHTs) providing family planning services
Number of subjects: 250
Study 33827502 — intervention group
Group type: EXPERIMENTAL
Intervention: VHTs of the same sex
Number of subjects: 250
Study 33827502 — intervention group
Group type: COMPARATOR
Intervention: Older VHTs of the opposite sex
Number of subjects: 250
Study 33827502 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about privacy and quality of care
Number of subjects: 250
Study 33827502 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about contraceptive side effects
Number of subjects: 250
Study 32216976 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy with protective cover of intraoral odontologic camera (PCIOC)
Number of subjects: 30
Study 32216976 — intervention group
Group type: COMPARATOR
Intervention: Videolaryngoscopy without protective cover of intraoral odontologic camera (PCIOC)
Number of subjects: 30
Study 32474062 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate restart of COC after taking UPA 30 mg
Number of subjects: 49
Study 32474062 — intervention group
Group type: COMPARATOR
Intervention: Delayed restart of COC after taking UPA 30 mg
Number of subjects: 49
Study 34617373 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient telecare based on nurse-led non-invasive assessments (AMULET model)
Number of subjects: 605
Study 34617373 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 605
Study 33191835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine administered by continuous intravenous infusion for 5 days in a novel Cremophor/Kolliphor EL-free lipid emulsion, NeuroSTAT
Number of subjects: 0
Study 33191835 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 32346981 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement and provisionalization
Number of subjects: 36
Study 34406551 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-tests
Number of subjects: 752
Study 33965603 — intervention group
Group type: EXPERIMENTAL
Intervention: CAL-DL-PDT (calcitriol followed by methyl aminolevulinate daylight photodynamic therapy)
Number of subjects: 42
Study 33965603 — intervention group
Group type: EXPERIMENTAL
Intervention: CAL-DL-PDT
Number of subjects: 42
Study 33965603 — intervention group
Group type: COMPARATOR
Intervention: P-DL-PDT (placebo followed by methyl aminolevulinate daylight photodynamic therapy)
Number of subjects: 42
Study 33965603 — intervention group
Group type: COMPARATOR
Intervention: P-DL-PDT
Number of subjects: 42
Study 32049299 — intervention group
Group type: EXPERIMENTAL
Intervention: For-profit hospice agencies
Number of subjects: 100
Study 32049299 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprofit hospice agencies
Number of subjects: 100
Study 32049299 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality of care
Number of subjects: 100
Study 32049299 — intervention group
Group type: EXPERIMENTAL
Intervention: Actionable criticisms
Number of subjects: 100
Study 32049299 — intervention group
Group type: EXPERIMENTAL
Intervention: Unactionable criticisms
Number of subjects: 100
Study 35587086 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 108
Study 35587086 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 108
Study 35587086 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 108
Study 34818873 — intervention group
Group type: EXPERIMENTAL
Intervention: BT200 (0.18-48mg) subcutaneously
Number of subjects: 112
Study 35706340 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Number of subjects: 148
Study 35706340 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 148
Study 32024465 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine combined with magnesium sulfate
Number of subjects: 11
Study 32024465 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine alone
Number of subjects: 11
Study 36067018 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleDiab group (telemedicine intervention)
Number of subjects: 200
Study 36067018 — intervention group
Group type: COMPARATOR
Intervention: Usual Care group (control)
Number of subjects: 200
Study 33370154 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based MVPA intervention
Number of subjects: 205
Study 36424261 — intervention group
Group type: EXPERIMENTAL
Intervention: D2+ lymphadenectomy
Number of subjects: 932
Study 36424261 — intervention group
Group type: EXPERIMENTAL
Intervention: Large tumors (≥5 cm)
Number of subjects: 932
Study 36424261 — intervention group
Group type: EXPERIMENTAL
Intervention: pT4
Number of subjects: 932
Study 36424261 — intervention group
Group type: EXPERIMENTAL
Intervention: pN3
Number of subjects: 932
Study 36424261 — intervention group
Group type: EXPERIMENTAL
Intervention: Undifferentiated histologic type
Number of subjects: 932
Study 33653982 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 40 ml of ropivacaine 0.5% at T9 level bilaterally
Number of subjects: 70
Study 33653982 — intervention group
Group type: COMPARATOR
Intervention: Control group (no procedure performed)
Number of subjects: 70
Study 33653982 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 70
Study 32495449 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam (RMZ) 5 mg and 10 mg
Number of subjects: 0
Study 32495449 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (MDZ) 2.5 mg and 5 mg
Number of subjects: 0
Study 32495449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32495449 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam (RMZ)
Number of subjects: 0
Study 32495449 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (MDZ)
Number of subjects: 0
Study 35766126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Regional Anesthesia (IVRA)
Number of subjects: 81
Study 35766126 — intervention group
Group type: COMPARATOR
Intervention: Periosteal Block
Number of subjects: 81
Study 35766126 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 81
Study 35766126 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 81
Study 35766126 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician's assessed ease of the anesthetic technique
Number of subjects: 81
Study 34081113 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 156
Study 34081113 — intervention group
Group type: COMPARATOR
Intervention: HMB (1500 mg daily)
Number of subjects: 156
Study 32654242 — intervention group
Group type: EXPERIMENTAL
Intervention: Maca (2 g/day for 12 weeks)
Number of subjects: 69
Study 32654242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 g/day for 12 weeks)
Number of subjects: 69
Study 34105988 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 20 min) applied over right/left dorsolateral prefrontal cortex (DLPFC) for 10 consecutive days
Number of subjects: 30